



February 27, 2020
JCR Pharmaceuticals Co., Ltd.

Translation

Notice of Organizational Changes and Personnel Changes

JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that organizational changes and personnel changes effective from April 1, 2020 as follows.

1. Organizational Changes

At the Sales Division, “West Japan Sales Department” will be divided into “Kinki-Hokuriku Sales Department” and “West Japan Sales Department” in order to promote attentive area marketing. “Production Planning Department” will be established in the Production Division as a support organization for problem solving across factories. At the Administration Division, “Human Resources & General Affairs Division” will be divided into “Human Resources Division” and “General Affairs Division” in order to ensure the efficient operation of each business. “Secretarial Office,” “Tokyo Office,” and “Information Systems Group” will be organizations under the direct control of the Administration Division, also “Information System Group” will be renamed “Information System Office”.

2. Change of Corporate Officers

Name	New Title	Current Title
Akihiro Haguchi	Senior Corporate Officer Head of Administration Division Executive Director, Administration Division	Corporate Officer Executive Director, Administration Division
Yutaka Honda	Senior Corporate Officer Head of Corporate Planning Division Executive Director, Corporate Planning Division	Corporate Officer Executive Director, Corporate Planning Division

3. Personnel Changes

Name	New Title	Current Title
Masaki Sumiyoshi	Senior Director, Administration Division Director, Human Resources Dept.	Senior Director, Administration Division Director, Human Resources & General Affairs Dept. Manager, Human Resources & General Affairs Group

Tsuyoshi Tajiri	Director, Kinki-Hokuriku Sales Dept. Sales Division	Manager, West Japan Sales Dept. Sales Division
Hideyuki Kobayashi	Principal, Sales Operations Dept. Sales Division	Director, Quality Assurance Dept. Manager, HQ Quality Assurance Division
Yukihiro Kuromoto	Director-Manager, Manufacturing Section, Murotani Plant Production Division	Director, Murotani Plant Director, Kobe API Plant Production Division
Yasushi Zenitani	Director, Kobe API Plant Production Division	Manager, Manufacturing Section, Kobe API Plant Production Division
Makoto Ashida	Director, Production Planning Dept. Production Division Associate Director, Human Resources Dept. Administration Division	Associate Director, Human Resources & General Affairs Dept. Administration Division
Toshiya Tomitsuka	Director, HQ Quality Assurance Dept. Quality Assurance Division Director, Quality Assurance Dept. Production Division	Director, HQ Quality Assurance Dept. Quality Assurance Division
Yoshio Hiyama	Director, Quality Assurance Dept. Manager, HQ Quality Assurance Division	Director, Production Division
Yoshihiro Izaki	Director, General Affairs Dept. Administration Division	Associate Director, Human resources & General Affairs Group, Human Resources & General Affairs Dept. Administration Division

[About JCR Pharmaceuticals]

JCR is a specialty pharma engaged in the research, development, manufacture and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy, “Contributing towards people’s healthcare through pharmaceutical products” drives JCR to create innovative pharmaceutical products as value-added treatment options for under-served patient communities.

[Cautionary Statement Regarding Forward-Looking Statements]

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors’ pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jcrpharm.co.jp

END

###